Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Selective Antigen Specific dTβRII-expressing T cells + B7-H3 CAR T cells
- Development stage
- Unknown
- Lead developer
- Children's National Research Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous cell-based biologic therapy, developed by the Children's National Research Institute, is a combination product consisting of two distinct T-cell populations administered in a 1:1 ratio: B7-H3-directed chimeric antigen receptor (CAR) T cells and PRAME-specific tumor antigen-specific T cells. The PRAME-specific T cells are engineered to express a dominant-negative TGF-beta receptor II (dTβRII), which is designed to shield the cells from the immunosuppressive effects of TGF-beta within the tumor microenvironment. This dual-targeting approach, referred to as CAR-TA therapy, is currently being investigated in the Phase I SABRE trial for pediatric and young adult patients with relapsed or refractory solid embryonal tumors, including rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor.
- Other names
- B7-H3 CAR+ T cells + DNR-PRAME TA-specific T cellsB7-H3 CAR+ T cells + dTBRII-transduced PRAME TA-specific T cellsSelective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
02
Targets
B7-H3PRAME peptide–HLA complex
Beyond the preview
Go deeper on Selective Antigen Specific dTβRII-expressing T cells + B7-H3 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selective Antigen Specific dTβRII-expressing T cells + B7-H3 CAR T cells.